Literature DB >> 22688657

Duration of prophylaxis with trimethoprim-sulfamethoxazole in patients undergoing solid organ transplantation.

P Malhotra, S D Rai, D Hirschwerk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22688657     DOI： 10.1007/s15010-012-0277-y

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  18 in total

Review 1.  A systematic review of two different trimetoprim-sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence.

Authors:  P Di Cocco; G Orlando; L Bonanni; M D'Angelo; K Clemente; S Greco; G Gravante; F Madeddu; C Scelzo; A Famulari; F Pisani
Journal:  Transplant Proc       Date:  2009-05       Impact factor: 1.066

Review 2.  Infectious complications of antilymphocyte therapies in solid organ transplantation.

Authors:  Nicolas C Issa; Jay A Fishman
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079

3.  Pneumocystis pneumonia in solid organ transplant recipients.

Authors:  S I Martin; J A Fishman
Journal:  Am J Transplant       Date:  2009-12       Impact factor: 8.086

4.  Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host.

Authors:  Hirohisa Yazaki; Norihiko Goto; Kazuharu Uchida; Takaaki Kobayashi; Hiroyuki Gatanaga; Shinichi Oka
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

5.  Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation.

Authors:  R T Schooley; M S Hirsch; R B Colvin; A B Cosimi; N E Tolkoff-Rubin; R T McCluskey; R C Burton; P S Russell; J T Herrin; F L Delmonico; J V Giorgi; W Henle; R H Rubin
Journal:  N Engl J Med       Date:  1983-02-10       Impact factor: 91.245

6.  Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients.

Authors:  S M Arend; R G Westendorp; F P Kroon; J W van't Wout; J P Vandenbroucke; L A van Es; F J van der Woude
Journal:  Clin Infect Dis       Date:  1996-06       Impact factor: 9.079

7.  Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case–control study.

Authors:  N De Castro; F Xu; R Porcher; J Pavie; J-M Molina; M-N Peraldi
Journal:  Clin Microbiol Infect       Date:  2010-09       Impact factor: 8.067

Review 8.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond.

Authors:  M Mohty
Journal:  Leukemia       Date:  2007-04-05       Impact factor: 11.528

9.  Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without steroids.

Authors:  Stephanie Louis; Marie Audrain; Diego Cantarovich; Barbara Schaffrath; Kay Hofmann; Uwe Janssen; Caroline Ballet; Sophie Brouard; Jean-Paul Soulillou
Journal:  Transplantation       Date:  2007-03-27       Impact factor: 4.939

10.  Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years.

Authors:  K E Orr; F K Gould; G Short; J H Dark; C J Hilton; P A Corris; R Freeman
Journal:  J Infect       Date:  1994-11       Impact factor: 6.072
View more
  1 in total

1.  Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patients.

Authors:  P Nickel; M Schürmann; H Albrecht; R Schindler; K Budde; T Westhoff; J Millward; N Suttorp; P Reinke; D Schürmann
Journal:  Infection       Date:  2014-08-29       Impact factor: 3.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.